Article

CPT code for novel AMD therapy effective July 1

NeoVista Inc. has announced that the American Medical Association Current Procedural Terminology Editorial Panel has released a new Category III code for the company's novel epiretinal beta radiation therapy to treat neovascular age-related macular degeneration.

Fremont, CA-NeoVista Inc. has announced that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel has released a new Category III code for the company's novel epiretinal beta radiation therapy to treat neovascular age-related macular degeneration (AMD). The new CPT code, 0190T, will become effective July 1 and will be used with the code for performing a basic posterior vitrectomy, 67036.

The assignment of a Category III code is a step toward the issuance of a Category I code, which is used by physicians to bill for their services and is tied to payment rates under many insurers' fees-for-service programs. During the Category III phase, the AMA and the Centers for Medicare and Medicaid Services collect data and assess new services and procedures. The data collected can be used in regulatory filings for a Category I code and for reimbursement following commercialization.

"We at NeoVista believe that our unique radiation therapy will eventually be shown to offer a less time-consuming and less-costly alternative for physicians who treat patients with wet AMD," said John Hendrick, president and chief executive officer of NeoVista.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.